Abstract：Objective To investigate the effect of Shenmai injection combined with spleen polypeptide on immune function in patients with colorectal cancer undergoing chemotherapy.Methods Eighty-eight patients with colorectal cancer were divided into the study group and the control group. All these patients underwent XELOX chemotherapy. The control group was treated with spleen polypeptide while the study group was additionally treated with Shenmai injection. The efficacy of the two groups was evaluated according to the efficacy criteria of RECIST solid tumors. Serum CD3+, CD4+, CD4+/CD8+ and NK cells were detected in the two groups before and after treatment. The quality of life of patients in the two groups was assessed by KPS. The incidence of adverse reactions in the two groups was recorded.Results The difference in the remission rate was not statistically significant between the two groups (P>0.05). The effective rate of the study group was higher than that of the control group. The difference was statistically significant (P<0.05). The levels of CD3+, CD4+, CD4+/CD8+ and NK cells in the study group were significantly higher than those in the control group after treatment. The difference was statistically significant (P<0.05). The quality of life was improved more significantly in the study group than in the control group. The difference was statistically significant (P<0.05). The incidence of nausea and vomiting, leukocyte reduction, liver injury and neurotoxicity in the study group was lower than that in the control group. The difference was of statistical significance (P<0.05).Conclusion Shenmai injection can enhance the curative effect of colorectal cancer chemotherapy while improving the immune function and quality of life of patients.
贾珍,罗梦琳. 参麦注射液对结直肠癌化疗患者免疫功能的影响[J]. 武警医学, 2019, 30(3): 221-223.
JIA Zhen, LUO Menglin. Effect of Shenmai injection combined with spleen polypeptide on immune function in patients with colorectal cancer undergoing chemotherapy. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(3): 221-223.
Eisenhauer E A, Verweij J, Eisenhauer E A, et al. 11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1[J]. EJC Supplements, 2009, 7(2):5.
2019, Vol. 30 
